Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
OnabotulinumtoxinA (BoNT-A) was first used to treat neurogenic lower urinary tract dysfunction (LUTD) 30 years ago. Recently, application of BoNT-A in LUTD have become more common since the approval of intravesical BoNT-A injection for patients with both overactive bladders (OAB) and neurogenic detr...
Main Authors: | Jia-Fong Jhang, Hann-Chorng Kuo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-06-01
|
Series: | Toxins |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6651/10/7/260 |
Similar Items
-
Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury
by: Sheng-Fu Chen, et al.
Published: (2022-01-01) -
Children with Non-Neurogenic Lower Urinary Tract Dysfunction Require Less Frequent and Number of Botulinum Toxin Injections Than Neurogenic Ones
by: Kamranbay Gasimov, et al.
Published: (2022-12-01) -
Real-World Data Regarding Satisfaction to Botulinum Toxin A Injection into the Urethral Sphincter and Further Bladder Management for Voiding Dysfunction among Patients with Spinal Cord Injury and Voiding Dysfunction
by: Cheng-Ling Lee, et al.
Published: (2022-01-01) -
Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
by: Yu-Hua Fan, et al.
Published: (2023-03-01) -
OnabotulinumtoxinA in Migraine: A Review of the Literature and Factors Associated with Efficacy
by: Jason C. Ray, et al.
Published: (2021-06-01)